Where Will Greenwich Lifesciences Inc (GLSI) Stock Go Next After It Has Risen 25.60% in a Week?

Greenwich Lifesciences Inc (GLSI) stock has risen 25.60% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Greenwich Lifesciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GLSI!

See Full GLSI Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GLSI Stock Today?

Greenwich Lifesciences Inc (GLSI) stock has risen 5.56% while the S&P 500 is down -0.94% as of 12:07 PM on Wednesday, Dec 28. GLSI has risen $0.86 from the previous closing price of $15.48 on volume of 27,514 shares. Over the past year the S&P 500 has fallen -20.83% while GLSI is down -31.34%. GLSI lost -$0.57 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Greenwich Lifesciences Inc click here.

More About Greenwich Lifesciences Inc

Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels. Click Here to get the full Stock Report for Greenwich Lifesciences Inc stock.